James Kasuboski

The Advanced Research Projects Agency for Health (ARPA-H) is committed to solving the most challenging problems in health by developing research programs dedicated to urgency, excellence and honesty. Part of the U.S. Department of Health and Human Services, ARPA-H aims to accelerate breakthroughs that empower every American to realize their full health potential – turning the seemingly impossible to the possible to the actual. The ARPA model is a continuous cycle of planning, implementing, and evaluating, and we’re looking for the best ideas and the brightest minds to carry out each process. Find more information about the agency and current job opportunities at https://arpa-h.gov

ReAx is a Chicago-based, pre-clinical company that is applying next generation chemical proteomic platforms to discover, optimize and validate small molecules directly in cells. The ReAx pipeline enables interrogation of proteomic ‘dark matter’ – a landscape that is rarely studied, much less exploited for ligand discovery against high-value protein targets. By integrating our platforms with innovative chemistry, disease biology, and computational methods, we hope to deliver first-in-class therapeutics in oncology and immunological disease indications.

We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease.

OMX Ventures is a venture capital firm focused on investing in a new era of bioengineering and its application for better tools, medicines, foods, industrial products, and more. We specialize in early-stage investments at the intersection of biology, big data, and AI, with a focus on therapeutics, bio tools, diagnostics, and synthetic biology platforms. We aim to help founders build strong teams, overcome key technical challenges in their first two years of operations, and grow into successful commercial enterprises. Before founding OMX, our partners invested early in successful biotech companies like 10X Genomics (TXG), Twist Bioscience (TWST), Ginkgo Bioworks (DNA), and QuantaLife (now part of Bio-Rad - BIO). Contact us: info@omx.vc

Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors. Through our proprietary EnTiCE platform, Enara is developing novel bispecific T cell engagers against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumors. Our partner, Boehringer Ingelheim, is combining multiple licensed Dark Antigens to create novel immunotherapies. Based in Oxford, UK, Enara Bio is backed by a strong syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, SV Health Investors, and the Francis Crick Institute. For more information, visit: www.enarabio.com. Comments and DMs to this account are not monitored, for any further information please head to our website

The Advanced Research Projects Agency for Health (ARPA-H) is committed to solving the most challenging problems in health by developing research programs dedicated to urgency, excellence and honesty. Part of the U.S. Department of Health and Human Services, ARPA-H aims to accelerate breakthroughs that empower every American to realize their full health potential – turning the seemingly impossible to the possible to the actual. The ARPA model is a continuous cycle of planning, implementing, and evaluating, and we’re looking for the best ideas and the brightest minds to carry out each process. Find more information about the agency and current job opportunities at https://arpa-h.gov

Luma Group is an investment firm focused on the greatest breakthrough scientific discoveries that leverage advanced computation and AI. Luma invests in discovering, developing and commercializing potentially high-caliber technologies to seek to improve human health and longevity. We aim to focus on the following areas in biotech: next generation therapeutics, AI/ML enabled drug discovery platforms, AI/ML technologies transforming early disease detection and patient care, and devices and tools with advanced data capture mechanisms and analysis capabilities. Luma is led by Partners Josh Fink, Dr. Themasap Khan, PhD, and Dr. Jamie Kasuboski, PhD, each with over a decade of biotech investing and operational experience. The Luma team is backed by an advisory network that includes former C-suite executives at Fortune 500 companies, seasoned executives with strong track records in building biotech companies and healthcare leaders. We seek to leverage the Firm’s strengths to invest in companies that have strong intellectual property protections, and which address large unmet medical needs. Our mission is to work closely with portfolio companies to help them focus on addressing untapped markets and generating shareholder value.

ReAx is a Chicago-based, pre-clinical company that is applying next generation chemical proteomic platforms to discover, optimize and validate small molecules directly in cells. The ReAx pipeline enables interrogation of proteomic ‘dark matter’ – a landscape that is rarely studied, much less exploited for ligand discovery against high-value protein targets. By integrating our platforms with innovative chemistry, disease biology, and computational methods, we hope to deliver first-in-class therapeutics in oncology and immunological disease indications.

We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease.